Recursion Pharmaceuticals (RXRX) Goodwill (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Goodwill data on file, last reported at $160.2 million in Q1 2026.

• Quarterly Goodwill rose 1.3% year-over-year to $160.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.2 million (up 1.3% YoY) and the FY2025 annual result came in at $162.2 million, up 8.92% from the prior year.
• Goodwill eased to $160.2 million in Q1 2026, from $162.2 million in the prior quarter.
• In the past five years, Goodwill ranged from a high of $164.3 million in Q2 2025 to a low of $801000.0 in Q2 2022.
• A 5-year average of $84.6 million and a median of $52.1 million in 2023 frame the typical range for Goodwill.
• Annual changes were most pronounced in 2022 — Goodwill changed 0.0% — and 2023, when it surged 6398.88%.
• Tracing RXRX's Goodwill over 5 years: stood at $801000.0 in 2022, then surged by 6398.88% to $52.1 million in 2023, then soared by 185.99% to $148.9 million in 2024, then climbed by 8.92% to $162.2 million in 2025, then declined by 1.23% to $160.2 million in 2026.
• The last three Goodwill figures came in at $160.2 million (Q1 2026), $162.2 million (Q4 2025), and $162.0 million (Q3 2025), per Business Quant data.